EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention

Pil Sang Song iD, Seok-Woo Seong iD, Ji-Yeon Kim iD, Soo Yeon An iD, Mi Joo Kim iD, Kye Taek Ahn iD, Seon-Ah Jin iD, Jin-Ok Jeong iD, Jeong Hoon Yang iD, Joo-Yong Hahn iD, Hyeon-Cheol Gwon iD, Woo Jin Jang iD und 4 weitere

Korean Circulation Journal · 2024 · 54 (4) · 189

DOI: 10.4070/kcj.2023.0268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Circulation Journal, 2024. Verfasst von Pil Sang Song und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Dae…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chungnam National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Concerns remain that early aspirin cessation may be associated with potential harm in subsets at high risk of ischemic events. This study aimed to assess the effects of P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) vs. prolonged DAPT (12-month or longer) based on the ischemic risk stratification, the CHADS-P2A2RC, after percutaneous coronary intervention (PCI). METHODS: This was a sub-study of the SMART-CHOICE trial. The effect of the randomized antiplatelet strategies was assessed across 3 CHADS-P2A2RC risk score categories. The primary outcome was a major adverse cardiac and cerebral event (MACCE), a composite of all-cause death, myocardial infarction, or stroke. RESULTS: Up to 3 years, the high CHADS-P2A2RC risk score group had the highest incidence of MACCE (105 [12.1%], adjusted hazard ratio [HR], 2.927; 95% confidence interval [CI], 1.358-6.309; p=0.006) followed by moderate-risk (40 [1.4%], adjusted HR, 1.786; 95% CI, 0.868-3.674; p=0.115) and low-risk (9 [0.5%], reference). In secondary analyses, P2Y12 inhibitor monotherapy reduced the Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding without increasing the risk of MACCE as compared with prolonged DAPT across the 3 CHADS-P2A2RC risk strata without significant interaction term (interaction p for MACCE=0.705 and interaction p for BARC types 2, 3, or 5 bleeding=0.055). CONCLUSIONS: The CHADS-P2A2RC risk score is valuable in discriminating high-ischemic-risk patients. Even in such patients with a high risk of ischemic events, P2Y12 inhibitor monotherapy was associated with a lower incidence of bleeding without increased risk of ischemic events compared with prolonged DAPT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.

Schlagwörter

Stichwörter der Autor:innen

AngioplastyCoronary artery diseaseDual anti-platelet therapyPrognosis

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
  • Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea. jojeong@cnu.ac.kr.
  • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
  • Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.

ORCID-Profile: Pil Sang Song, Seok-Woo Seong, Ji-Yeon Kim, Soo Yeon An, Mi Joo Kim, Kye Taek Ahn, Seon-Ah Jin, Jin-Ok Jeong, Jeong Hoon Yang, Joo-Yong Hahn, Hyeon-Cheol Gwon, Woo Jin Jang, Hyuck Jun Yoon, Jang-Whan Bae, Woong Gil Choi, Young Bin Song

Förderung

  • Chungnam National University

Zitieren

APA

Song, P. S., Seong, S. W., Kim, J. Y., An, S. Y., Kim, M. J., Ahn, K. T., Jin, S. A., Jeong, J. O., Yang, J. H., Hahn, J. Y., Gwon, H. C., Jang, W. J., Yoon, H. J., Bae, J. W., Choi, W. G., & Song, Y. B. (2024). The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention. Korean Circulation Journal, 54(4), 189. https://doi.org/10.4070/kcj.2023.0268

Vancouver

Song PS, Seong SW, Kim JY, An SY, Kim MJ, Ahn KT, et al. The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention. Korean Circulation Journal. 2024;54(4):189. doi:10.4070/kcj.2023.0268

BibTeX
@article{Song2024,
  author = {Song, Pil Sang and Seong, Seok-Woo and Kim, Ji-Yeon and An, Soo Yeon and Kim, Mi Joo and Ahn, Kye Taek and Jin, Seon-Ah and Jeong, Jin-Ok and Yang, Jeong Hoon and Hahn, Joo-Yong and Gwon, Hyeon-Cheol and Jang, Woo Jin and Yoon, Hyuck Jun and Bae, Jang-Whan and Choi, Woong Gil and Song, Young Bin},
  title = {The Association of CHADS-P2A2RC Risk Score With Clinical Outcomes in Patients Taking P2Y12 Inhibitor Monotherapy After 3 Months of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention},
  journal = {Korean Circulation Journal},
  year = {2024},
  volume = {54},
  number = {4},
  pages = {189},
  doi = {10.4070/kcj.2023.0268}
}
Kostenlos starten →